Loading
A phase 2 trial of Mirdametinib in Langerhans cell histiocytosis and Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, run by Children's Hospital Medical Center, Cincinnati, now recruiting.
Mirdametinib in Histiocytic Disorders is a phase 2 interventional study registered as NCT06153173 by Children's Hospital Medical Center, Cincinnati, with 40 participants planned, started 2024-02-05 and due to reach its primary completion in 2030-03. Interventions recorded: Mirdametinib. Conditions recorded: Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders.
Linked to the drug Mirdametinib because the registry names it among its interventions and Langerhans cell histiocytosis and Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms among its conditions. Registry record only: no result has been read by an editor.
Shares Mirdametinib and the tag pipeline.
Shares Mirdametinib and the tag pipeline.
Shares Langerhans cell histiocytosis (LCH) and the tag pipeline.
Shares Langerhans cell histiocytosis (LCH), Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms.
Shares Langerhans cell histiocytosis (LCH), Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms.
Shares Langerhans cell histiocytosis (LCH), Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms.